"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Descriptor ID |
D017024
|
MeSH Number(s) |
E02.186.170 E02.319.170
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2010 | 0 | 3 | 3 |
2011 | 0 | 2 | 2 |
2013 | 0 | 2 | 2 |
2014 | 0 | 5 | 5 |
2015 | 0 | 2 | 2 |
2016 | 2 | 1 | 3 |
2017 | 0 | 1 | 1 |
2018 | 0 | 6 | 6 |
2019 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
2021 | 0 | 2 | 2 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer. 2022 06; 126(12):1715-1724.
-
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 01; 7(8):1149-1157.
-
The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Anticancer Res. 2021 Jun; 41(6):2849-2858.
-
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res. 2020 10 23; 22(1):111.
-
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Int J Cancer. 2019 08 01; 145(3):857-868.
-
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). Clin Exp Metastasis. 2018 12; 35(8):777-783.
-
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol. 2018 08 01; 29(8):1777-1783.
-
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial. Clin Breast Cancer. 2018 10; 18(5):e1103-e1110.
-
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018 05 01; 36(13):1308-1316.
-
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Clin Breast Cancer. 2018 04; 18(2):175-183.